SEMESTRE 1 | |||||||||
S1 2022 (en million d'euros) | Total chiffre d'affaires | Var. TCC | Var. Publiée | Etats-Unis | Var. TCC | Europe | Var. TCC | Reste du monde | Var. TCC |
Dupixent | 3,577 | 44.4% | 56.2% | 2,653 | 38.0% | 450 | 55.0% | 474 | 75.5% |
Aubagio | 1,017 | -4.4% | 2.3% | 689 | -6.3% | 269 | 1.5% | 59 | -9.4% |
Lemtrada | 45 | 0.0% | 4.7% | 19 | -15.0% | 12 | 9.1% | 14 | 16.7% |
Kevzara | 172 | 46.0% | 52.2% | 90 | 64.0% | 53 | 29.3% | 29 | 36.4% |
Neurologie & Immunologie | 1,234 | 0.7% | 7.3% | 798 | -1.8% | 334 | 5.4% | 102 | 4.1% |
Cerezyme | 367 | 5.5% | 7.0% | 94 | 2.4% | 126 | 1.6% | 147 | 11.0% |
Cerdelga | 139 | 7.3% | 13.0% | 75 | 6.3% | 55 | 7.8% | 9 | 12.5% |
Myozyme | 487 | -3.3% | 0.8% | 163 | -17.8% | 206 | 2.5% | 118 | 10.7% |
Nexviazyme | 73 | 6700.0% | 7200.0% | 63 | - | 3 | 200.0% | 7 | - |
Fabrazyme | 458 | 5.8% | 11.2% | 221 | 5.3% | 116 | 4.5% | 121 | 8.1% |
Aldurazyme | 133 | 4.9% | 8.1% | 29 | 0.0% | 45 | 4.7% | 59 | 7.4% |
Total maladies rares | 1,695 | 6.7% | 10.9% | 645 | 7.4% | 553 | 4.2% | 497 | 9.0% |
Jevtana | 203 | -20.8% | -15.4% | 142 | 8.4% | 19 | -74.7% | 42 | -8.7% |
Fasturtec | 86 | 8.1% | 16.2% | 54 | 14.0% | 24 | 9.1% | 8 | -22.2% |
Libtayo | 88 | 44.1% | 49.2% | - | - | 70 | 43.8% | 18 | 45.5% |
Sarclisa | 129 | 67.6% | 74.3% | 55 | 78.6% | 38 | 40.7% | 36 | 89.5% |
Total Oncologie | 507 | 7.4% | 13.4% | 251 | 20.0% | 151 | -12.8% | 105 | 20.0% |
Alprolix | 237 | 9.0% | 18.5% | 198 | 10.5% | - | - | 39 | 2.6% |
Eloctate | 291 | -3.2% | 4.7% | 232 | -2.8% | - | - | 59 | -4.8% |
Cablivi | 97 | 9.5% | 15.5% | 48 | 2.3% | 47 | 17.5% | 2 | 0.0% |
Total maladies hématologiques rares | 629 | 3.7% | 11.9% | 482 | 3.8% | 47 | 17.5% | 100 | -2.0% |
Médecine de spécialités | 7,642 | 19.8% | 27.8% | 4,829 | 20.4% | 1,535 | 13.6% | 1,278 | 25.7% |
Lovenox | 714 | -9.5% | -7.0% | 7 | -60.0% | 353 | -4.1% | 354 | -12.7% |
Toujeo | 541 | 4.4% | 8.2% | 128 | -4.2% | 211 | 8.2% | 202 | 5.9% |
Plavix | 508 | 0.0% | 4.7% | 5 | -20.0% | 52 | -13.3% | 451 | 2.1% |
Multaq | 178 | 7.9% | 17.9% | 160 | 9.8% | 9 | -25.0% | 9 | 28.6% |
Thymoglobulin | 210 | 12.8% | 22.1% | 121 | 7.9% | 17 | 6.3% | 72 | 23.6% |
Mozobil | 124 | 6.4% | 12.7% | 71 | 6.7% | 31 | 6.9% | 22 | 4.8% |
Praluent | 197 | 79.8% | 89.4% | 55 | 860.0% | 108 | 42.7% | 34 | 33.3% |
Soliqua/iGlarLixi | 106 | 10.0% | 17.8% | 56 | -3.8% | 15 | 7.1% | 35 | 43.5% |
Rezurock | 84 | - | - | 84 | - | - | - | - | - |
Autres produits stratégiques | 543 | -0.8% | 4.0% | 86 | -36.6% | 182 | 4.0% | 275 | 15.2% |
Produits Stratégiques | 3,205 | 5.3% | 10.4% | 773 | 13.4% | 978 | 3.5% | 1,454 | 2.9% |
Lantus | 1,271 | -6.7% | -1.4% | 425 | -10.3% | 223 | -9.3% | 623 | -3.3% |
Aprovel | 245 | 15.5% | 22.5% | 3 | 0.0% | 42 | -10.6% | 200 | 24.0% |
Autres produits non stratégiques | 2,320 | -7.9% | -5.2% | 196 | -6.3% | 593 | -10.1% | 1,531 | -7.3% |
Produits Non Stratégiques | 3,836 | -6.4% | -2.5% | 624 | -9.0% | 858 | -9.9% | 2,354 | -4.2% |
Ventes Industrielles | 316 | -18.9% | -16.8% | 13 | -54.2% | 294 | -13.7% | 9 | -61.9% |
Médecine Générale | 7,357 | -2.3% | 1.9% | 1,410 | 1.0% | 2,130 | -4.8% | 3,817 | -2.0% |
Total Pharma | 14,999 | 7.7% | 13.7% | 6,239 | 15.4% | 3,665 | 2.1% | 5,095 | 3.9% |
Vaccins Polio / Petussis / HIB | 1,202 | 9.1% | 14.2% | 224 | -15.4% | 161 | 11.0% | 817 | 17.5% |
Vaccins Rappel | 261 | 18.4% | 26.7% | 144 | 15.0% | 74 | 12.1% | 43 | 48.1% |
Vaccins Méningite | 265 | -21.3% | -15.6% | 185 | -19.3% | 6 | 500.0% | 74 | -30.2% |
Vaccins contre la grippe | 181 | -10.7% | -7.7% | 12 | - | 37 | 105.6% | 132 | -28.7% |
Vaccins pour voyageurs et autres vaccins endémiques | 243 | 73.7% | 82.7% | 74 | 83.3% | 42 | 215.4% | 127 | 47.6% |
Vaccins | 2,198 | 7.8% | 13.5% | 678 | -2.1% | 321 | 31.1% | 1,199 | 8.2% |
Allergie | 418 | 13.4% | 21.9% | 249 | 13.5% | 37 | 8.8% | 132 | 14.7% |
Toux et rhume | 219 | 96.4% | 99.1% | - | - | 122 | 165.2% | 97 | 46.9% |
Douleur | 618 | 13.8% | 17.0% | 103 | 2.2% | 289 | 15.6% | 226 | 17.1% |
Santé Digestive | 661 | 11.5% | 15.4% | 62 | -8.2% | 224 | 12.0% | 375 | 15.1% |
Bien-être physique | 173 | 5.0% | 8.8% | - | - | 11 | -15.4% | 162 | 6.8% |
Bien-être mental | 123 | 13.1% | 15.0% | 24 | -4.3% | 60 | 9.1% | 39 | 34.5% |
Hygiène personnelle | 279 | 1.6% | 10.7% | 209 | -0.5% | 1 | -50.0% | 69 | 10.2% |
Autres | 102 | -22.3% | -21.5% | (2) | -175.0% | 37 | -32.1% | 67 | -6.8% |
Santé Grand Public | 2,593 | 13.1% | 17.8% | 645 | 2.6% | 781 | 19.4% | 1,167 | 14.9% |
Total Sanofi | 19,790 | 8.4% | 14.2% | 7,562 | 12.4% | 4,767 | 6.2% | 7,461 | 6.2% |
TRIMESTRE 2 | |||||||||
T2 2022 (en million d'euros) | Total chiffre d'affaires | Var. TCC | Var. Publiée | Etats-Unis | Var. TCC | Europe | Var. TCC | Reste du monde | Var. TCC |
Dupixent | 1,963 | 43.4% | 57.9% | 1,477 | 37.9% | 239 | 56.6% | 247 | 65.3% |
Aubagio | 526 | -2.2% | 6.5% | 360 | -2.8% | 137 | 3.0% | 29 | -17.1% |
Lemtrada | 20 | 0.0% | 5.3% | 8 | -30.0% | 6 | 0.0% | 6 | 100.0% |
Kevzara | 77 | 30.4% | 37.5% | 40 | 40.0% | 25 | 25.0% | 12 | 18.2% |
Neurologie & Immunologie | 623 | 1.1% | 9.5% | 408 | -0.6% | 168 | 5.7% | 47 | -2.0% |
Cerezyme | 202 | 18.8% | 22.4% | 49 | 0.0% | 66 | 8.2% | 87 | 42.6% |
Cerdelga | 72 | 11.5% | 18.0% | 39 | 9.4% | 28 | 12.0% | 5 | 25.0% |
Myozyme | 252 | -3.6% | 1.6% | 81 | -21.7% | 103 | 1.0% | 68 | 18.5% |
Nexviazyme | 43 | 3900.0% | 4200.0% | 37 | - | 2 | 100.0% | 4 | - |
Fabrazyme | 238 | 9.3% | 16.7% | 116 | 6.2% | 58 | 7.4% | 64 | 17.0% |
Aldurazyme | 64 | 7.0% | 12.3% | 16 | 0.0% | 21 | 10.0% | 27 | 8.7% |
Total maladies rares | 891 | 11.6% | 17.4% | 338 | 7.6% | 279 | 6.5% | 274 | 22.9% |
Jevtana | 105 | -15.8% | -7.9% | 74 | 8.2% | 8 | -73.3% | 23 | -4.3% |
Fasturtec | 46 | 7.7% | 17.9% | 30 | 18.2% | 12 | 9.1% | 4 | -33.3% |
Libtayo | 47 | 36.4% | 42.4% | - | - | 36 | 38.5% | 11 | 28.6% |
Sarclisa | 64 | 52.5% | 60.0% | 30 | 62.5% | 16 | 14.3% | 18 | 90.0% |
Total Oncologie | 263 | 8.0% | 16.4% | 134 | 19.2% | 72 | -11.1% | 57 | 17.4% |
Alprolix | 129 | 16.0% | 29.0% | 106 | 12.0% | - | - | 23 | 35.3% |
Eloctate | 153 | -3.5% | 6.3% | 124 | -3.5% | - | - | 29 | -3.2% |
Cablivi | 51 | 4.3% | 10.9% | 26 | 9.5% | 24 | 0.0% | 1 | - |
Total maladies hématologiques rares | 336 | 5.5% | 15.9% | 259 | 5.1% | 24 | 0.0% | 53 | 10.4% |
Médecine de spécialités | 4,076 | 21.6% | 32.0% | 2,616 | 21.4% | 782 | 15.2% | 678 | 30.9% |
Lovenox | 337 | -10.9% | -8.2% | 2 | -50.0% | 168 | -7.7% | 167 | -13.7% |
Toujeo | 267 | 2.4% | 8.1% | 70 | 5.2% | 107 | 6.9% | 90 | -4.5% |
Plavix | 247 | 0.0% | 5.6% | 2 | -33.3% | 26 | -16.1% | 219 | 3.0% |
Multaq | 91 | 2.5% | 15.2% | 82 | 2.9% | 4 | -33.3% | 5 | 66.7% |
Thymoglobulin | 113 | 12.0% | 22.8% | 65 | 3.6% | 9 | 12.5% | 39 | 27.6% |
Mozobil | 66 | 6.9% | 13.8% | 40 | 9.4% | 16 | 6.7% | 10 | 0.0% |
Praluent | 128 | 147.9% | 166.7% | 55 | - | 55 | 41.0% | 18 | 77.8% |
Soliqua/iGlarLixi | 53 | 4.3% | 15.2% | 26 | -11.1% | 7 | 14.3% | 20 | 33.3% |
Rezurock | 43 | - | - | 43 | - | - | - | - | - |
Autres produits stratégiques | 266 | -3.5% | 3.5% | 47 | -35.8% | 87 | -2.2% | 132 | 17.0% |
Produits Stratégiques | 1,611 | 6.0% | 12.8% | 432 | 21.3% | 479 | 0.6% | 700 | 2.4% |
Lantus | 600 | -12.1% | -5.8% | 217 | -19.0% | 111 | -7.4% | 272 | -8.2% |
Aprovel | 120 | 13.1% | 21.2% | 2 | 100.0% | 21 | -12.5% | 97 | 20.3% |
Autres produits non stratégiques | 1,133 | -8.5% | -4.8% | 101 | -10.1% | 293 | -11.3% | 739 | -7.1% |
Produits Non Stratégiques | 1,853 | -8.6% | -3.8% | 320 | -16.0% | 425 | -10.4% | 1,108 | -5.5% |
Ventes Industrielles | 133 | -33.3% | -30.7% | 3 | -84.6% | 126 | -30.7% | 4 | - |
Médecine Générale | 3,597 | -4.1% | 1.4% | 755 | 0.3% | 1,030 | -8.9% | 1,812 | -2.6% |
Total Pharma | 7,673 | 7.9% | 15.7% | 3,371 | 16.0% | 1,812 | 0.1% | 2,490 | 4.9% |
Vaccins Polio / Petussis / HIB | 589 | 7.9% | 13.3% | 99 | -17.0% | 83 | 23.9% | 407 | 12.4% |
Vaccins Rappel | 152 | 32.1% | 43.4% | 91 | 24.6% | 43 | 34.4% | 18 | 77.8% |
Vaccins Méningite | 153 | -24.7% | -17.7% | 109 | -26.7% | 4 | 300.0% | 40 | -25.9% |
Vaccins contre la grippe | 115 | -5.9% | -3.4% | - | - | 33 | 266.7% | 82 | -28.2% |
Vaccins pour voyageurs et autres vaccins endémiques | 145 | 83.8% | 95.9% | 51 | 100.0% | 25 | 200.0% | 69 | 54.5% |
Vaccins | 1,178 | 8.7% | 15.3% | 372 | -3.5% | 188 | 59.8% | 618 | 5.5% |
Allergie | 192 | 16.2% | 29.7% | 118 | 11.7% | 20 | 25.0% | 54 | 23.7% |
Toux et rhume | 98 | 74.5% | 78.2% | - | - | 56 | 166.7% | 42 | 17.6% |
Douleur | 304 | 5.8% | 10.5% | 57 | -2.0% | 138 | 7.8% | 109 | 7.3% |
Santé Digestive | 336 | 9.3% | 15.9% | 33 | -19.4% | 112 | 18.9% | 191 | 10.1% |
Bien-être physique | 85 | 2.6% | 9.0% | - | - | 5 | 0.0% | 80 | 2.7% |
Bien-être mental | 57 | 0.0% | 5.6% | 12 | -8.3% | 26 | 0.0% | 19 | 6.3% |
Hygiène personnelle | 149 | 5.5% | 17.3% | 113 | 6.3% | - | -100.0% | 36 | 6.5% |
Autres | 44 | -29.0% | -29.0% | 2 | -100.0% | 18 | -33.3% | 24 | -27.8% |
Santé Grand Public | 1,265 | 9.1% | 16.2% | 335 | 3.1% | 375 | 17.9% | 555 | 6.8% |
Total Sanofi | 10,116 | 8.1% | 15.7% | 4,078 | 12.7% | 2,375 | 5.7% | 3,663 | 5.3% |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Sanofi SA published this content on 28 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 July 2022 07:57:01 UTC.